TECOS, Merck's Cardiovascular Safety Trial of JANUVIA, Met Primary Endpoint in Patients with Type 2 Diabetes
June 10, 2015 at 07:02 AM EDT
Merck (NYSE: MRK) known as MSD outside Canada and the United States, announced the primary results of the Trial Evaluating ...
